|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 272.60 SEK | -3.20% |
|
-7.03% | -14.11% |
| 06-12 | Swedish Orphan Biovitrum AB - Special Call | |
| 06-12 | Sobi presents new clinical data on hematological diseases at congress | FW |
| Capitalization | 93.63B 9.7B 8.41B 7.93B 7.2B 13.31B 840B 15.03B 35.87B 384B 36.4B 35.62B 1,426B | P/E ratio 2025 * |
20.2x | P/E ratio 2026 * | 15.1x |
|---|---|---|---|---|---|
| Enterprise value | 102B 10.54B 9.13B 8.61B 7.82B 14.46B 912B 16.32B 38.96B 417B 39.54B 38.69B 1,549B | EV / Sales 2025 * |
3.61x | EV / Sales 2026 * | 2.99x |
| Free-Float |
51.66% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Swedish Orphan Biovitrum AB
More recommendations
More press releases
| 1 day | -3.20% | ||
| 1 week | -7.03% | ||
| Current month | -7.03% | ||
| 1 month | -11.78% | ||
| 3 months | -7.09% | ||
| 6 months | -10.86% | ||
| Current year | -14.11% |
| 1 week | 271.2 |  | 291.2 |
| 1 month | 271.2 | | 312.6 |
| Current year | 241.8 | | 349.4 |
| 1 year | 241.8 | | 354.4 |
| 3 years | 197.9 | | 354.4 |
| 5 years | 127.1 | | 354.4 |
| 10 years | 89.5 | | 354.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 60 | 22/05/2017 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 58 | 20/07/2018 |
| Chief Tech/Sci/R&D Officer | 54 | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 05/05/2011 | |
Staffan Schüberg
BRD | Director/Board Member | 56 | 01/01/2020 |
| Director/Board Member | 69 | 01/01/2021 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 1.15% | 240 M€ | -4.79% | - | |
| 0.9% | 4 M€ | +17.62% | - | |
| 0.48% | 0 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.20% | -7.03% | -0.29% | +29.13% | 9.69B | ||
| +0.63% | -0.35% | -18.02% | -6.16% | 74.6B | ||
| +1.70% | +1.60% | +34.57% | +22.12% | 51.48B | ||
| -0.10% | -3.70% | +13.27% | +100.64% | 34.36B | ||
| +0.40% | -3.98% | -43.20% | -37.03% | 18.54B | ||
| -0.96% | -3.78% | +103.67% | +188.85% | 16.51B | ||
| +0.78% | -4.99% | +52.94% | +725.40% | 14.98B | ||
| -0.04% | -.--% | +74.71% | +140.03% | 14.02B | ||
| +0.28% | -1.10% | +11.43% | -3.94% | 13.22B | ||
| +1.62% | -6.86% | -4.44% | -41.91% | 10.75B | ||
| Average | +0.11% | -2.65% | +22.46% | +111.71% | 25.81B | |
| Weighted average by Cap. | +0.48% | -1.91% | +14.50% | +74.28% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 28.14B 2.92B 2.53B 2.38B 2.16B 4B 252B 4.52B 10.78B 115B 10.94B 10.71B 429B | 31.64B 3.28B 2.84B 2.68B 2.43B 4.5B 284B 5.08B 12.12B 130B 12.3B 12.04B 482B |
| Net income | 4.61B 478M 414M 390M 355M 655M 41.35B 740M 1.77B 18.92B 1.79B 1.75B 70.22B | 6.1B 632M 548M 517M 470M 868M 54.74B 979M 2.34B 25.05B 2.37B 2.32B 92.94B |
| Net Debt | 8.06B 836M 724M 683M 620M 1.15B 72.33B 1.29B 3.09B 33.1B 3.13B 3.07B 123B | 941M 97.53M 84.53M 79.67M 72.42M 134M 8.44B 151M 361M 3.86B 366M 358M 14.33B |
More financial data
* Estimated data
Employees
1,895
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/06/25 | 272.60 kr | -3.20% | 412,364 |
| 18/06/25 | 281.60 kr | +0.36% | 419,371 |
| 17/06/25 | 280.60 kr | -2.77% | 316,574 |
| 16/06/25 | 288.60 kr | +1.26% | 378,418 |
| 13/06/25 | 285.00 kr | -2.80% | 441,716 |
Delayed Quote Nasdaq Stockholm, June 19, 2025 at 08:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
272.60SEK
Average target price
353.09SEK
Spread / Average Target
+29.53%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SOBI Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition